3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
3
Active Trials
180 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Suzhou Alphamab Co., Ltd. is a company with 3 orphan drug designations across 3 rare diseases. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hemophilia A | recombinant humanized anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody | Des.TrialAppr. |
| hemophilia B | recombinant humanized anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody | Des.TrialAppr. |
| von Willebrand disease (hereditary or acquired) | recombinant humanized anti-TFPI monoclonal antibody | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio